Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
The first fruit of a long-standing deal with Roche enters phase 1 in March.
An FDA verdict is due in the third quarter, as Protagonist looks likely to opt out.
The month saw the first commissioner's priority voucher approval in oncology.
But biomarker enrichment and toxicity remain key for FX-909.
Welireg looks headed to regulators in second-line and adjuvant kidney cancer.
The company will license EGFR and cMet inhibitors from Celyn.
